Ramucirumab plus erlotinib is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.1 In this exclusive video, Dr. Maximillian Hochmair discusses the roadmap for the improvement in treatment decisions in patients with EGFR mutated advanced NSCLC.
Reference 1. Cyramza Abridged Pack Insert, May 2021 (India).
China Reports First Commercial Brain-Computer Interface Implant for Spinal Cord Injury
Anatomy & Physiology
2h ago
56
Rare Triple Procedure Addresses Breast Cancer and Silent Cardiac Disease in One Operation
Cardiology
2h ago
51
What is Your Diagnosis for This Patient with a Painless Lesion on the Tongue?
Oral and Maxillofacial Surgery
8h ago
106
India Adds Nearly 10,000 MBBS Seats for 2026 to 2027 Academic Session
Allergy & Immunology
9h ago
164
Andhra Pradesh Reports 12 COVID-19 Infections and Four Deaths Between June 26 and July 16
Anesthesiology
14h ago
174
1
Mumbai Reports Nearly Threefold Rise in H1N1 Cases During First Half of 2026
Anesthesiology
1d ago
576
3